Sentinel Asset Management’s Myriad Genetics MYGN Stock Holding History

Sentinel Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-535,950	Closed	-$11.2M	–	271
2013 Q4	$11.2M	Sell	535,950 -94,000	-15%	-$2.38M	0.22%	177
2013 Q3	$14.8M	Buy	629,950 +247,200	+65%	+$7.02M	0.31%	143
2013 Q2	$10.3M	Buy	+382,750	New	+$11.1M	0.22%	185

Other funds holding MYGN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Sentinel Asset Management's MYGN Position: Q1 2014 in Review

Sentinel Asset Management sold out of Myriad Genetics (MYGN) in Q1 2014, closing a stake of 535,950 shares — an estimated $11.2M sold.

Sentinel Asset Management first reported a position in MYGN in Q2 2013 and held it in 3 quarters. The position peaked at $14.8M in Q3 2013. 280 funds tracked by Wall St. Rank hold MYGN as of Q1 2014.

Sentinel Asset Management reported no remaining Myriad Genetics position as of Q1 2014 after selling out during the quarter.
Sentinel Asset Management sold 535,950 Myriad Genetics shares in Q1 2014, an estimated $11.2M.
Sentinel Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 3 quarters.
Sentinel Asset Management's Myriad Genetics position peaked at $14.8M in Q3 2013.
280 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2014.

Based on Sentinel Asset Management's 13F filing for Q1 2014, filed 15 May 2014.